cagrilintide novo nordisk with semaglutide Nordisk: Engineering a Comeback for a Strong 2026 Trajectory In the REDEFINE 2 phase
In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Novo touts CagriSema's win over semaglutide in pivotal diabetes study cagrilintide fda Novo Nordisk Submits CagriSema for FDA Approval for Obesity Treatment Dr. Jibran Khan Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide
Pay in 4 interest-free payments of $6.67 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6



